FDA — authorised 15 December 2008
- Marketing authorisation holder: ABBVIE
- Status: approved
🇺🇸 Trilipix in United States
FDA authorised Trilipix on 15 December 2008
Marketing authorisations
FDA — authorised 15 December 2008
- Application: NDA022224
- Marketing authorisation holder: ABBVIE
- Local brand name: TRILIPIX
- Indication: CAPSULE, DELAYED RELEASE — ORAL
- Status: approved
Trilipix in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in United States
Frequently asked questions
Is Trilipix approved in United States?
Yes. FDA authorised it on 15 December 2008; FDA authorised it on 15 December 2008.
Who is the marketing authorisation holder for Trilipix in United States?
ABBVIE holds the US marketing authorisation.